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CLINICAL FOCUS: NEUROLOGICAL AND PSYCHIATRIC DISORDERS
REVIEW

On demand therapy for Parkinson’s disease patients: Opportunities and choices
Robert A. Hausera, Peter A. LeWittb,c and Cynthia L. Comellad
a

Parkinson's Disease and Movement Disorders Center, Department of Neurology, University of South Florida, Tampa, Florida, USA; bDepartment of
Neurology, Wayne State University School of Medicine, Detroit, Michigan, USA; cParkinson's Disease and Movement Disorders Center Henry Ford
Hospital, West Bloomfield, Michigan, USA; dDepartment of Neurological Sciences, Section of Parkinson Disease and Movement Disorders, Rush
University Medical Center, Chicago,Illinois, USA
ABSTRACT

Levodopa is the most effective symptomatic treatment for Parkinson’s disease (PD), but a major
treatment challenge is that over time, many patients experience periods of return of PD symptoms
intermittently through the day, known as OFF periods. OFF periods typically manifest as a return of
motor symptoms but can also involve non-motor symptoms and these periods can disrupt good
control despite optimization of the oral levodopa regimen. OFF periods emerge in large measure due
to a shortening of the duration of clinical benefit from oral levodopa, thought to be related to
a progressive loss of dopamine neurons and their ability to store and release levodopa-derived
dopamine over many hours. The problem is further compounded by impaired absorption of oral
levodopa due to gastroparesis and other factors limiting its uptake in the small intestine, including
competition for uptake by meals and their protein content. On-demand therapies are now available for
the treatment of OFF episodes in PD and are administered intermittently, on an as-needed basis, on top
of the patient’s maintenance medication regimen. To be useful, an on-demand medication should take
effect more rapidly and reliably than oral levodopa. Options for on-demand therapy for OFF periods
have recently increased with the approval of levodopa inhalation powder and sublingual apomorphine
as alternatives to the older option of subcutaneous apomorphine injection, each of which avoids the
gastrointestinal tract and its potential for absorption delay. On-demand therapy is now available for
patients experiencing episodic or intermittent need for rapid and reliable onset of benefit. On-demand
therapy may also provide an alternative to more invasive treatment such as infusion of levodopa/
carbidopa intestinal gel and for patients whose OFF episodes are not controlled despite deep brain
stimulation.

Introduction
The goal of treatment for Parkinson’s disease (PD) varies with
each patient’s symptoms but, in general, treatment aims to
reduce discomforts or disabilities in the quest of improving
overall function and quality of life. Currently, there are no
treatments that slow or stop disease progression [1,2].
Levodopa is the most effective symptomatic treatment for
PD [1,3]. A major treatment challenge for this amino acid
precursor of dopamine is that many patients eventually
develop inconsistency in its effectiveness. Patients then
experience a return of PD symptoms within relatively short
periods of time despite their standard levodopa therapy,
known as motor fluctuations or OFF periods [4]. OFF periods
can also involve non-motor symptoms [5]. OFF periods may
occur even with an oral regimen that has been adjusted to
optimize its effect [4].
When PD patients are initially treated with oral levodopa
preparations, they typically experience a good response that is
maintained through the day when the medication is adminis
tered using a traditional TID regimen. However, over time, the
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duration of benefit from each levodopa dose shortens and the
time to onset of benefit increases and becomes more variable.
These two factors lead to response fluctuations through
the day, consisting of times when there is good control of
symptoms (called ON), and other times when benefit has worn
off or not yet kicked in, with reemergence of parkinsonian
signs and symptoms (called OFF). The exact reasons for the
development of motor fluctuations are not fully elucidated,
but it is thought that with the progressive loss of dopamine
neurons over time, the ability of remaining neurons to store
and release levodopa-derived dopamine over many hours is
diminished and the duration of benefit from each levodopa
dose shortens [5,6]. In addition, since levodopa is absorbed in
the proximal small intestine, worsening gastroparesis may
increase the time to absorption of oral levodopa, thereby
delaying onset of benefit and increasing variability [7,8]. In
addition, factors limiting levodopa’s uptake in the small intes
tine, including competition for uptake by meals and their
protein content, have a greater effect [9,10]. Infection with
Helicobacter pylori may also be a factor as it has been shown
to be associated with worse clinical motor outcomes in
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a number of studies when compared with antibiotictreated or non-infected controls [11].
The incidence of OFF periods becomes increasingly pre
valent with chronic levodopa therapy. The prevalence of
motor fluctuations in prospective studies of levodopatreated PD patients is almost 50% within 5 years of starting
levodopa therapy and increases beyond two thirds after
9 years or more of treatment [1,12]. In the prospective,
early detection of wearing off in Parkinson disease (DEEP)
study of 617 patients with an average treatment duration of
6.6 years, wearing-OFF was observed in 56.9% of patients by
neurologists and in 67.3% by the self-administered WearingOff Questionnaire (WOQ-19). Wearing-OFF was common
even in patients with early PD as it was observed in 21.8%
of patients with <2.5 years of disease duration by neurolo
gists and 41.8% by the WOQ-19 [13]. Factors increasing risk
for wearing OFF include younger age, female sex, and
greater than average levodopa doses [13,14]. OFF periods
are one factor that has a deleterious impact on activities of
daily living and quality of life [14–17]. In the OFF PARK
survey, the most troublesome symptoms associated with
OFF periods were slowness, reduced dexterity, fatigue, and
slowness in the morning (morning akinesia) [16]. Despite
the challenge of improving control of PD to lessen OFF
events, many patients and physicians do not recognize or
even understand OFF symptoms and this problem is often
insufficiently treated [18–20].
Various pharmacological treatments and medication
adjustment strategies are used to manage OFF periods and
motor fluctuations. These include shortening the interval
between levodopa administrations and lowering individual
doses (to reduce the likelihood of dyskinesias); using
extended-release levodopa formulations; adding dopamine
agonists (orally administered or transdermal patches), mono
amine oxidase B inhibitors (MAO-B) inhibitors, catecholO-methyltransferase (COMT) inhibitors, an adenosine A2A inhi
bitor (istradefylline), or amantadine; or switching to levodopa/
carbidopa intestinal gel infusion [1]. Continuous subcutaneous
apomorphine infusion is also available in many European
countries [21].
Beyond baseline medication adjustments, OFF time can
be reduced by deep brain stimulation (DBS) of the globus
pallidus interna or subthalamic nucleus [22]. Aims for all of
these treatments are to reduce the metabolic breakdown of
levodopa (MAO-B and COMT inhibitors), provide additional
and more sustained stimulation to dopamine receptors
(dopaminergic agonists), provide more constant plasma
levodopa concentrations (dose fractionation, extendedrelease formulations, and carbidopa/levodopa intestinal
gel), or directly stimulate targets downstream from the
nigrostriatal dopaminergic synapses (DBS, amantadine, or
adenosine A2A receptor inhibition) [1,3,23,24]. All of these
medications, additions or adjustments, and surgical inter
ventions can become part of the patient’s maintenance
regimen and are typically not considered ‘on-demand’ or
‘as needed’ therapies. Despite the availability of these treat
ments, many patients still experience OFF episodes and
additional treatments can be considered.

On-demand treatment in PD: general considerations
Another approach to helping patients manage OFF periods is
to use an on-demand therapy. On-demand therapies are those
that can be used as needed to bring about improvement
quickly and reliably when an OFF episode occurs. To provide
a relatively rapid response, those that are currently available
bypass the GI tract and the difficulties of delayed absorption
encountered by oral levodopa. These include subcutaneous
apomorphine injection, sublingual apomorphine, and inhaled
levodopa. These medications can be used on an as needed
basis when the patient experiences an OFF episode. Such
episodes may be expected or unexpected. For example,
some patients may only use an on-demand therapy once
a week, when an unexpected OFF episode occurs. For others,
unpredictable OFF episodes may occur more frequently and
on-demand treatment may be required several times a day. In
other situations, the need for an on-demand therapy may not
be so unexpected. For example, many patients find that their
first morning oral levodopa dose takes a long time to kick in
and would benefit from the addition of the regular use of an
‘on-demand’ therapy upon waking each morning. In a study of
orally administered immediate-release and extended-release
carbidopa/levodopa (Rytary®) in fasted PD patients with
motor fluctuations, the mean onset of action was about
50 minutes (0.81/0.83 hours) [25]. In this situation, the use of
an on-demand therapy every morning would become part of
the patient’s maintenance regimen. Another example might
be the patient who experiences an OFF episode every day
after eating lunch. There are also patients who use on-demand
treatments to fill in gaps (i.e. OFF periods) between oral
levodopa doses on a regular basis through the day if the
duration of benefit is short and it takes a while for the next
oral levodopa dose to kick in. In these cases, the ‘on-demand
therapy’ is being scheduled on a regular basis and becomes
part of the patient’s maintenance regimen.

On-demand therapies for PD (Table 1)
Subcutaneous apomorphine
Apomorphine injection for subcutaneous use (Apokyn®, US
WorldMeds, LLC, Louisville, KY) achieved US Food and
Drug Administration (FDA) approval in 2004 as an acute,
intermittent therapy for OFF episodes. It provides relief
from OFF states for many patients at 10 minutes and its
benefits may last for up to 2 hours [26,29]. It is adminis
tered via a multiple-dose pen injector. Due to possible AEs
of nausea and vomiting, premedication with an antiemetic
(trimethobenzamide) is recommended for initiation of
treatment, and some patients continue to use it whenever
they use apomorphine [38]. Since apomorphine was initi
ally used for PD in the mid-1980s, there is a considerable
number of open-label studies supporting its use for treat
ing OFF periods [27]. In a randomized, double-blind, pla
cebo-controlled study, 29 patients who experienced at
least 2 hours of daily OFF time received subcutaneous
apomorphine in both inpatient and outpatient settings.
In the outpatient phase, injections reversed 95% of OFF
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Table 1. Pharmacological on-demand treatments for Parkinson’s disease OFF periods.
Drug

Indication (US)

Subcutaneous
Indicated for the acute,
apomorphine
intermittent treatment of
(Apokyn ) [26hypomobility, 'off' episodes
29
('end-of-dose wearing off'
and unpredictable 'on/off'
episodes) in patients with
advanced Parkinson’s
disease. Apokyn has been
studied as an adjunct to
other medications

Administration
●

®

●

●

●

Sublingual
apomorphine
(Kynmobi )
[30,31]

™

Indicated for the acute,
intermittent treatment of
OFF episodes in patients
with Parkinson’s disease

●

●

Dose

Subcutaneous
injection using
Apokyn pen
injector and glass
cartridge
Cartridge con
tains 3 mL/30 mg
apomorphine HCl
(10 mg/mL)
Single cartridge,
pen and needle
can deliver doses
up to 1 mL
(10 mg) in
0.02 mL (0.2 mg)
increments
Max 5 doses/day

●

Sublingual film,
10 mg, 15 mg,
20 mg, 25 mg,
30 mg dose
strengths
Max 5 doses/day

●

●

●

Starting
dose
0.2 mL
starting
dose
Titrate up
to 0.6 mL
depending
on effec
tiveness
and toler
ance

Initial dose
10 mg
Titrate up
to 30 mg
depending
on effec
tiveness
and toler
ance

●
●
●

●

●

●

●
●

●

Inhaled
levodopa
(Inbrija ) [3237]

®

Indicated for the intermittent
treatment of OFF episodes
in patients with Parkinson’s
disease treated with
carbidopa/levodopa

●

●
●

Orally inhaled
using a provided
inhaler and
capsules
One dose per
OFF period
Max 5 doses/day

●

One dose
consists of
2 × 42 mg
capsules
(84 mg)

Common
TEAEs*

Efficacy*

●

●
●

●

Time to onset of action:
7.3–22 min
Duration of effect: 62.6–
96 min
Reduction in OFF time: 1)
58% vs placebo 2)
2 hours vs placebo
Significant improvement
in UPDRS-III scores vs
placebo
Significant efficacy as
recorded by Columbia
Parkinson’s disease score

●

Improvement in UPDRSIII score noted at 15 min
post dose (1st
measurement
timepoint)†
Duration of effect: up to
90 min (last timepoint)
Significant improvement
in UPDRS-III scores vs
placebo (LS mean treat
ment difference vs pla
cebo −7.6 30 min after
dosing at week 12)
35% of apomorphine
patients turned ON
30 min post dose vs 16%
on placebo

●
●

Improvement in UPDRSIII score noted at 10 min
post dose (first
measurement
timepoint)†
Duration of effect: up to
60 min (last timepoint)
Significant improvement
in UPDRS-III scores vs
placebo (LS mean treat
ment difference vs pla
cebo −3.07 30 min after
dosing at week 12
(84 mg))
58% of Inbrija 84 mg
patients turned ON by
60 min post dose vs 36%
on placebo

●

●
●

●
●
●
●
●

●

●
●
●

●

●
●

Comment

Nausea and/
or vomiting
Dyskinesia
Dizziness/
postural
hypotension
Rhinorrhea
Somnolence/
drowsiness
Yawning
Hallucination/
confusion
Edema/swel
ling of extre
mities

●

Nausea
Oral/pharyn
geal soft tis
sue swelling
Oral/pharyn
geal soft tis
sue pain and
paresthesia
Dizziness
Somnolence
Most com
mon AEs
leading to
discontinua
tion were
oropharyn
geal disorders
(17%)

●

Cough
Upper
respiratory
tract infection
Sputum
discolored
Most com
mon AE lead
ing to
discontinua
tion was
cough (2%)

●

●

●

●

Premedicate with
antiemetic (e.g.
trimethobenzamide)
to minimize nausea
and vomiting at
start of treatment
Contraindicated with
5HT3 antagonists,
including antiemetics
ondansetron, grani
setron, dolasetron,
palonosetron, alose
tron

Premedicate with
antiemetic (e.g.
trimethobenzamide)
to minimize nausea
and vomiting at
start of treatment
Contraindicated with
5HT3 antagonists

Contraindicated
with nonselective
MAO inhibitors or in
those who have
taken a nonselective
MAO inhibitor
within 2 weeks
Not recommended in
those with asthma,
COPD, or another
chronic underlying
lung disease

Note: ‘improvements’ are from a predose, OFF state. Negative UPDRS scores represent improvement.
*Summary of double-blind studies. †Subjects were on standard anti-Parkinsonian regimens including levodopa.
AE, adverse event; LS, least squares; TEAE, treatment-emergent adverse event; UPDRS-III, Unified Parkinson Disease Rating Scale Part III (motor).

episodes, as compared with 23% for placebo (P < 0.001).
Similar results were observed with inpatient testing [39]. In
a study of 56 patients with advanced PD, a significant
response was seen at the prespecified end point of 20 min
utes, an effect that lasted at least 90 minutes after admin
istration. Maximum improvement was detected at
40 minutes, though anti-parkinsonian effect can begin as
early as 4 minutes after injection. Continued efficacy with
repeated use over 3 months was demonstrated in 62
patients with advanced PD who showed significant

improvement in the Unified Parkinson’s Disease Rating
Part III (motor) scale (UPDRS-III) compared with placebo
when tested at 10 minutes post administration [40].
Subcutaneous apomorphine was also demonstrated to be
effective for managing morning akinesia. In a study of
patients (n = 127) on levodopa therapy with morning
akinesia, the mean time to ON was reduced from
60.9 ± 18.1 minutes with levodopa alone to 23.7 ± 14.6 min
utes with levodopa plus subcutaneous apomorphine.
Nausea and dizziness were the most common AEs [41]. In
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a long-term open-label safety study (n = 546) of patients
using subcutaneous apomorphine daily, the most common
AEs were nausea and vomiting, dyskinesia, dizziness, som
nolence, hallucination, yawning, and injection site bruising
[42]. An expert consensus guideline that recommended
subcutaneous apomorphine emphasized that management
of AEs was the key to successful therapy [43]. Patient
acceptance has been limited due to aversion to or discom
fort with self-administered injections, and the develop
ment of skin nodules or ulcers at injection sites.
Prescribers should be aware that subcutaneous apomor
phine contains sodium metabisulfite. Patients with a sulfite
sensitivity may experience allergic-type reactions, includ
ing urticaria, rash, pruritus, angioedema, anaphylactic
symptoms, and life-threatening or less severe asthmatic
attacks. Patients who experience any hypersensitivity/aller
gic reaction to subcutaneous apomorphine should avoid
taking it again [28].

Sublingual apomorphine
Sublingual
apomorphine
(Kynmobi™,
Sunovion
Pharmaceuticals, Inc., Marlborough, MA) is a buffered form
of apomorphine that is administered via a layered thin film.
When placed under the tongue for 3 minutes, the film
dissolves and releases the drug. It was approved by the
FDA in 2020 for a similar indication to subcutaneously
injected apomorphine [31]. Prior efforts at development of
an oral apomorphine were unsuccessful because after gas
trointestinal absorption, the drug undergoes extensive
hepatic first-pass metabolism [44]. Sublingual apomorphine
overcomes this limitation through direct delivery of the
drug into the circulation across the buccal surface [45].
Sublingual apomorphine may be perceived as a more prac
tical treatment than subcutaneous apomorphine due to its
convenience. Like subcutaneous injection of the drug, pre
medication with trimethobenzamide in an effort to reduce
possible nausea and vomiting is recommended [46].
Concomitant use of 5HT3 antagonist anti-emetics such as
ondansetron are contraindicated in light of the possibility
for causing profound hypotension. In a randomized, con
trolled phase 3 study in 109 patients, sublingual apomor
phine was more effective than placebo in improving motor
function 30 minutes after administration, as measured by
the Movement Disorder Society UPDRS Part 3 (MDS-UPDRSIII). The least squares mean treatment difference for dosing
with up to 35 mg apomorphine vs placebo was −7.6 rating
points (P = 0.0002). A self-rated ‘full on’ within 30 minutes
was reported in 35% of apomorphine patients compared
with 16% of placebo patients (P = 0.050). The most com
mon adverse events were oropharyngeal events such as
mouth and pharyngeal irritation in 31% of patients; this
led to trial discontinuation in 17%. Nausea occurred in
28% of the apomorphine patients during the double-blind
phase of the study, and somnolence and dizziness were
reported in 13% and 9%, respectively [30]. Similar to sub
cutaneous apomorphine, sublingual apomorphine contains
sodium metabisulfite, a sulfite that may cause allergic-type

reactions, including anaphylactic symptoms
threatening or less severe asthmatic episodes.

and

life-

Inhaled levodopa
Another on-demand treatment is levodopa inhalation powder
(Inbrija®, Acorda Therapeutics, Inc. Ardsley, NY). This product
received FDA approval in 2018 for the intermittent treatment
of OFF episodes in PD patients also being treated with carbi
dopa/levodopa [47]. Levodopa inhalation powder uses a dry
powder inhaler system (Arcus® technology) for delivery of
a levodopa therapeutic dose from two capsules by oral inhala
tion into the lungs for direct and rapid absorption into the
circulation, thereby avoiding the delays that the gastrointest
inal tract can impose for levodopa uptake [48]. Patients inhale
the powdered drug from the passive delivery system by slowly
inhaling [49]. The use of levodopa inhalation powder is not
recommended for individuals with asthma, chronic obstructive
pulmonary disease, or other chronic lung disease [47]. In its
phase 3 study, two doses of levodopa inhalation powder (60
and 84 mg) were evaluated in a randomized placebocontrolled trial (n = 351) lasting 12 weeks. The improvement
in UPDRS-III score from pre-dose to the primary study end
point assessment at 30 minutes post-dose at week 12 was
significantly greater with inhaled levodopa 84 mg than with
placebo. The most common AE in the inhaled levodopa 84 mg
group was cough (15%). Most cough was mild in intensity and
represented an irritant effect from inhaling dry powder. Three
patients discontinued the study due to cough [34]. Levodopa
inhalation powder was also shown to be safe for use as an
early morning OFF treatment in a separate, double-blind
crossover safety study in 36 patients [33]. A pharmacokinetic
study in 23 fed patients demonstrated that an 84 mg dose of
inhaled levodopa increased plasma levodopa concentrations
much more rapidly and with less variation in concentration
than an oral dose of carbidopa/levodopa 25/100 mg. Plasma
concentrations of inhaled levodopa showed a mean increase
of ~140 ng/mL by 5 minutes and ~240 ng/mL by 15 minutes
after inhalation, whereas for oral carbidopa/levodopa,
a substantial increase in plasma levodopa concentration was
not seen until 60 minutes post-dose. Between-subject levo
dopa plasma concentration variability for inhaled levodopa
84 mg was generally less than for oral carbidopa/levodopa
25 mg/100 mg [37].

Potential candidates for on-demand therapy
One of the biggest challenges to the implementation of ondemand therapies is a recognition of their impact on qualityof-life measures as reported by patients. Many patients are
unaware of how to recognize OFF periods and what treatment
options are available. Patient-physician communication about
OFF period experiences can be submerged in a typical out
patient visit if not specifically questioned.
As summarized above, there are three on-demand medica
tion options for patients who are experiencing OFF periods.
How these medications fit into PD treatment guidelines has
not yet been clarified. Levodopa inhalation powder and
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sublingual apomorphine may be preferred over apomorphine
subcutaneous injections by some patients as they have non
invasive delivery, are easy to administer, and are intended for
safe combination with existing treatment regimens [46,49].
The mean duration of action of subcutaneous and sublingual
[50] apomorphine is less than one hour, and both modalities
have treatment-limiting side effects. Hypotensive responses,
nausea, and vomiting can occur even with low doses of the
drug. In contrast, lowered blood pressure is not a limiting
adverse event with inhaled levodopa powder. Its duration of
effect has not yet been characterized in controlled clinical
trials as evaluation of efficacy has only been measured out
to 60 minutes post-dose [51]. A 60-minute duration of action is
also typical of subcutaneous apomorphine administration.
At present, the main value of on-demand medications is to
equip patients with the means for rapid and reliable relief of
OFF symptoms. It is worth stating, however, that the treat
ment of non-motor symptoms, many of which fluctuate in
concert with OFF periods, remains a largely unmet need in
Parkinson’s disease and non-motor symptoms constitute an
important part of a patient’s quality of life. None of the ondemand medications discussed above have been systemati
cally evaluated for these symptoms, but this remains an active
area of research [5,52].
In future development of consensus treatment guidelines
for PD, inclusion of on-demand therapies may eliminate this
current gap in treatment recommendations and suggest how
on-demand therapies might best be used in clinical practice.
Further trials directly comparing the efficacy and tolerability
of these treatments would also be beneficial. Some patients
may want or need a rapid-acting medication for regular or
situational use (for example, for the first dose of the day after
awakening or when socializing at dinnertime), while others
may control OFF episodes solely by adjustments to their
existing regimen of oral medications. In general, patients
who are receiving oral immediate-release carbidopa/levo
dopa 3-times per day and are experiencing wearing OFF
motor fluctuations on a regular basis throughout the day
need to decrease the time between levodopa intake by
using 4–5 doses per day (based on a 3-4-hour duration of
effect). If a patient has made such an adjustment and is,
nonetheless, still experiencing wearing OFF fluctuations reg
ularly, a maintenance adjunct medication (such as an inhibi
tor of COMT or MAO-B, or an adenosine A2a antagonist) may
be considered. However, on-demand therapies may be an
important part of a therapeutic regimen when changes in
maintenance regimens do not reliably eliminate OFF
episodes.
An obvious, attractive target for on-demand therapies is
morning OFF. Morning OFFs are experienced by many
patients with motor fluctuations while awaiting onset of
effect for their first dose of levodopa. Some patients may
not be troubled or inconvenienced by the delay. Others may
have to prepare for work or have household or other respon
sibilities requiring their attention; some may become fru
strated or upset by this motor dysfunction; some simply
may not like the inconvenience of waiting. In these cases, ondemand therapies may provide motor benefit more quickly
than oral levodopa alone.
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Another scenario where on-demand therapies may fill an
unmet need is for those patients who would benefit from
‘spot’ therapy on occasion or who experience troublesome
OFF episodes at unexpected times. The patient who reports
unwanted OFF episodes even just a few times per week and
without a predictable pattern might also be a good candidate
for on-demand therapy. In addition, some patients anticipating
an OFF episode might feel more comfortable carrying this treat
ment option every day. For some people, the need for an ondemand dose may be as infrequent as once per month, though
the availability of such treatment may enhance their motivation
and perception of safety, encouraging them to continue with
more activities outside the home. Even the patient on immedi
ate-release carbidopa/levodopa who leads an active lifestyle
may want to stick with the convenience of that regimen as
long as possible and supplement with an on-demand therapy
only at times when OFF episodes interfere with activities.
On-demand therapies may also be useful for patients who
experience OFF episodes in relation to meals. Although the timing
of medication intakes can be adjusted to mealtimes, there can still
be a disruption of regular levodopa effects for several hours after
meals. Each of the on-demand treatments bypass the GI tract and
can address the problem of meal-related OFF periods.
Many patients with advanced PD experience OFF periods
that are highly unpredictable despite multiple maintenance
medications and cannot be managed with dosage adjustment
or fractionation. For some of these patients, on-demand thera
pies may be preferred as an alternative to intestinal infusion
with levodopa/carbidopa gel or DBS.
Finally, on-demand therapies may be considered for treat
ing overnight OFF episodes when relatively rapid relief is
sought in order to regain mobility or relieve Parkinsonian
symptoms to get back to sleep.

Conclusion
The options for on-demand therapy for OFF periods have
increased with the approval of levodopa inhalation powder
and sublingual apomorphine as alternatives to the initial
option of subcutaneous apomorphine injection. On-demand
medications may be added to oral medication regimens when
OFF periods are inadequately controlled. As motor fluctuations
become more frequent and capricious, the use of on-demand
therapy should be considered in patients who have episodic
needs for rapid and reliable onset of action. On-demand ther
apy may also provide an alternative to more invasive treat
ment such as levodopa/carbidopa intestinal gel and for
patients whose OFF episodes are not controlled despite DBS.
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